Abstract
Proteins are currently the major drug targets and thus play a critical role in the process of modern drug design. This typically involves construction of drug compounds based on the structure of a drug target, validation for therapeutic efficacy of the drug compounds, evaluation of drug toxicity, and finally, clinical trial. Proteomics, defined as the comprehensive analysis of the proteins that are expressed in cells or tissues, can be employed at different stages of this process. Comparative proteomics can distinguish subtle changes in protein abundance at a depth of several thousand proteins at different conditions i.e. normal vs disease, to facilitate drug target identification. Also, chemical proteomics can be used to determine drug-target interactions and systematically analyze drug specificity and selectivity. Moreover, phosphoproteomics can be employed to monitor changes in phosphorylation events to characterize drug actions on cell signaling pathways. Similarly, functional proteomics can be utilized to investigate protein-protein and protein-ligand interactions for the clarification of the mechanism of drug action, identification of disease-related sub-networks and novel drug targets. Furthermore, quantitative proteomics can be used to characterize long-term drug effects on protein expression. In addition, computational approaches have emerged to convert complex proteomic data into sophisticated computer models of cellular protein networks. In this review, we will provide an overview of these state-of-the-art proteomics techniques, describe their underlying experimental concepts and compare them to each other, and discuss existing and future applications in the art of drug design and development.
Keywords: Proteomics, mass spectrometry, drug design, drug target discovery, drug-target interaction, post-translational modifications, protein interaction networks
Current Computer-Aided Drug Design
Title: Applications of Current Proteomics Techniques in Modern Drug Design
Volume: 6 Issue: 3
Author(s): Cheng-Cheng Zhang and Juergen Kast
Affiliation:
Keywords: Proteomics, mass spectrometry, drug design, drug target discovery, drug-target interaction, post-translational modifications, protein interaction networks
Abstract: Proteins are currently the major drug targets and thus play a critical role in the process of modern drug design. This typically involves construction of drug compounds based on the structure of a drug target, validation for therapeutic efficacy of the drug compounds, evaluation of drug toxicity, and finally, clinical trial. Proteomics, defined as the comprehensive analysis of the proteins that are expressed in cells or tissues, can be employed at different stages of this process. Comparative proteomics can distinguish subtle changes in protein abundance at a depth of several thousand proteins at different conditions i.e. normal vs disease, to facilitate drug target identification. Also, chemical proteomics can be used to determine drug-target interactions and systematically analyze drug specificity and selectivity. Moreover, phosphoproteomics can be employed to monitor changes in phosphorylation events to characterize drug actions on cell signaling pathways. Similarly, functional proteomics can be utilized to investigate protein-protein and protein-ligand interactions for the clarification of the mechanism of drug action, identification of disease-related sub-networks and novel drug targets. Furthermore, quantitative proteomics can be used to characterize long-term drug effects on protein expression. In addition, computational approaches have emerged to convert complex proteomic data into sophisticated computer models of cellular protein networks. In this review, we will provide an overview of these state-of-the-art proteomics techniques, describe their underlying experimental concepts and compare them to each other, and discuss existing and future applications in the art of drug design and development.
Export Options
About this article
Cite this article as:
Zhang Cheng-Cheng and Kast Juergen, Applications of Current Proteomics Techniques in Modern Drug Design, Current Computer-Aided Drug Design 2010; 6 (3) . https://dx.doi.org/10.2174/157340910791760064
DOI https://dx.doi.org/10.2174/157340910791760064 |
Print ISSN 1573-4099 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6697 |
Call for Papers in Thematic Issues
Artificial Intelligence in Biomedical Research: Enhancing Data Analysis for Drug Discovery and Development
This thematic issue highlights the transformative impact of Artificial Intelligence (AI), with a particular focus on Machine Learning (ML) and Deep Learning (DL) techniques, in advancing biomedical research. As a result of these cutting-edge AI methodologies, drug discovery and development are revolutionizing data analysis. Rapid advances in artificial intelligence technologies ...read more
Computer-Aided Drug Discoveries for Emerging Diseases
Computer-aided drug design is a rapidly growing research field that continues to gain momentum, attracting increasing interest from the scientific community. This trend is largely driven by the growing utilization of machine learning and artificial intelligence in drug design and discovery. Artificial Intelligence has proven efficacy across various applications, including ...read more
Deep Learning Approaches in Bioinformatics for Computer-Aided Drug Development Targeting Brain Tumors
The integration of deep learning and bioinformatics is revolutionizing the field of computer-aided drug development, particularly in the fight against brain tumors one of the most aggressive and lethal types of cancer. Brain tumors present significant challenges due to their heterogeneity and complexity, which require novel approaches for early diagnosis ...read more
Emerging Trends in Computer-Aided Drug and Healthcare Solutions
This special issue aims to further the advancement of knowledge in drug design, healthcare innovations, and medical solutions by leveraging modern computational techniques. In recent years, computer-aided drug design has transformed the approach to medicinal chemistry, accelerating the drug discovery process and fostering innovation. The goal of this issue is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Novel Aspects of Natural and Modified Vinca Alkaloids
Current Medicinal Chemistry - Anti-Cancer Agents Nitric Oxide, Peroxynitrite, Peroxynitrous Acid, Nitroxyl, Nitrogen Dioxide, Nitrous Oxide: Biochemical Mechanisms and Bioaction
Current Bioactive Compounds Emerging Therapeutic Approaches Based on Nanotechnology for the Treatment of Diseases Associated with Telomere Dysfunction
Mini-Reviews in Medicinal Chemistry Treatment of Interstitial Lung Disease Associated with Polymyositis- Dermatomyositis: An Update
Current Respiratory Medicine Reviews SNAP-tag based Agents for Preclinical In Vitro Imaging in Malignant Diseases
Current Pharmaceutical Design Trabectedin (Yondelis®) as a Therapeutic Option in Gynecological Cancers: A Focus on its Mechanisms of Action, Clinical Activity and Genomic Predictors of Drug Response
Current Drug Targets Scheduling of Taxanes: A Review
Current Clinical Pharmacology Diterpenoids- Potential Chemopreventive and Chemotherapeutic Agents in Leukemia
Current Pharmaceutical Biotechnology Biosafety of Onco-Retroviral Vectors
Current Gene Therapy Use of Exogenous Enzymes in Human Therapy: Approved Drugs and Potential Applications
Current Medicinal Chemistry Molecular Mechanisms and Proposed Targets for Selected Anticancer Gold Compounds
Current Topics in Medicinal Chemistry Production of Alpha Emitters for Targeted Alpha Therapy
Current Radiopharmaceuticals Integrin αvβ3 Antagonists for Anti-Angiogenic Cancer Treatment
Recent Patents on Anti-Cancer Drug Discovery Involvement of Targeting and Scaffolding Proteins in the Regulation of the EGFR/Ras/MAPK Pathway in Oncogenesis
Current Signal Transduction Therapy Characterization of Human Tyrosinase Ectodomain Expressed in Escherichia coli
Protein & Peptide Letters Role of Glucocorticoids in Breast Cancer
Current Pharmaceutical Design Chitosan Formulations as Carriers for Therapeutic Proteins
Current Drug Discovery Technologies ZFPM2-AS1: An Oncogenic Long Non-coding RNA in Multiple Cancer Types
Mini-Reviews in Medicinal Chemistry Future Developments in Osteoporosis Therapy
Endocrine, Metabolic & Immune Disorders - Drug Targets Milk Fat Globule Epidermal Growth Factor VIII Signaling in Arterial Wall Remodeling
Current Vascular Pharmacology